Loading…

Clinical features of gamma-hydroxybutyrate and gamma-butyrolactone toxicity and concomitant drug and alcohol use

To describe the clinical features of gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL) toxicity. Retrospective case-study of 65 GHB and GBL intoxications seen in an urban emergency department. 63% of intoxications occurred in male patients. The median age was 24 years (range 16–41 years). 65...

Full description

Saved in:
Bibliographic Details
Published in:Drug and alcohol dependence 2006-02, Vol.81 (3), p.323-326
Main Authors: Liechti, Matthias E., Kunz, Isabelle, Greminger, Peter, Speich, Rudolf, Kupferschmidt, Hugo
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To describe the clinical features of gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL) toxicity. Retrospective case-study of 65 GHB and GBL intoxications seen in an urban emergency department. 63% of intoxications occurred in male patients. The median age was 24 years (range 16–41 years). 65% co-ingested alcohol or illicit drugs, mostly MDMA and cocaine. 83% presented with coma. The mean ± S.D. time to regain consciousness among comatose patients was 111 ± 61 min and was significantly longer in patients who co-abused illicit drugs such as cocaine or MDMA (155 ± 60 min). Bradycardia occurred in 38%, hypotension in 6% and hypothermia in 48%. Agitation was observed in 17% of all patients and was significantly more frequent in patients with alcohol co-use (29%). Vomiting occurred in 31% of all patients and tended to be more frequent in patients who co-used alcohol (39%). Management of GHB and GBL overdose was supportive. Four patients needed admission to an intensive care unit for mechanical ventilation (6%). Overdosing of GHB and GBL frequently results in non-reactive coma reflecting the severity of poisoning. Multiple drug use is common and significantly influences the clinical presentation.
ISSN:0376-8716
1879-0046
DOI:10.1016/j.drugalcdep.2005.07.010